BCX-1777 in Treating Patients With Refractory Cancer

NIAID Data Ecosystem2026-03-06 收录

药物临床试验

转移性癌症治疗

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2010182 数据链接链接失效反馈

官方服务：

资源简介：

RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.

创建时间：

2003-04-15

Summary results for Xeloda noninferiority trial from Rothmann’s, Wang’s, and Ratio tests, and GPV-based method.

药物临床试验

统计分析

Summary results for Xeloda noninferiority trial from Rothmann’s, Wang’s, and Ratio tests, and GPV-based method.

figshare.com2023-06-03 更新30

Table 1_Characteristics of pediatric interventional drug trials registered between 2015 and 2024 on ClinicalTrials.gov.xlsx

药物临床试验

药物剂型与给药途径分析

AimThis study comprehensively analyzed the characteristics and development trends of pediatric interventional drug clinical trials registered between 2015 and 2024, with a focus on pharmaceutical char

NIAID Data Ecosystem00

Dataset from A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)

克罗恩病治疗

药物临床试验

This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's dis

NIAID Data Ecosystem00

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

儿科肿瘤

药物临床试验

The PI3K/Akt/mTOR signaling pathway is aberrantly activated in various pediatric tumors. We conducted a phase I study of the Akt inhibitor perifosine in patients with recurrent/refractory pediatric CN

NIAID Data Ecosystem30

Dataset from A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID).

药物临床试验

胃肠溃疡预防

The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD), compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term ther

NIAID Data Ecosystem00

BCX-1777 in Treating Patients With Refractory Cancer

资源简介：

相关数据集